IL241001A0 - muscarinic agonists - Google Patents
muscarinic agonistsInfo
- Publication number
- IL241001A0 IL241001A0 IL241001A IL24100115A IL241001A0 IL 241001 A0 IL241001 A0 IL 241001A0 IL 241001 A IL241001 A IL 241001A IL 24100115 A IL24100115 A IL 24100115A IL 241001 A0 IL241001 A0 IL 241001A0
- Authority
- IL
- Israel
- Prior art keywords
- muscarinic agonists
- muscarinic
- agonists
- Prior art date
Links
- 239000000472 muscarinic agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790364P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/026998 WO2014152144A1 (en) | 2013-03-15 | 2014-03-14 | Muscarinic agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL241001A0 true IL241001A0 (en) | 2015-11-30 |
Family
ID=50439523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL241001A IL241001A0 (en) | 2013-03-15 | 2015-09-01 | muscarinic agonists |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9670209B2 (enExample) |
| EP (1) | EP2976079A1 (enExample) |
| JP (1) | JP2016513677A (enExample) |
| KR (1) | KR20150143439A (enExample) |
| CN (1) | CN105120865A (enExample) |
| AU (1) | AU2014240139A1 (enExample) |
| BR (1) | BR112015021271A2 (enExample) |
| CA (1) | CA2903276A1 (enExample) |
| IL (1) | IL241001A0 (enExample) |
| MX (1) | MX2015012043A (enExample) |
| RU (1) | RU2015144155A (enExample) |
| TW (1) | TW201446761A (enExample) |
| WO (1) | WO2014152144A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9670209B2 (en) | 2013-03-15 | 2017-06-06 | Acadia Pharmaceuticals Inc. | Muscarinic agonists |
| KR101613245B1 (ko) | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| US9822122B2 (en) | 2016-03-31 | 2017-11-21 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5707798A (en) | 1993-07-13 | 1998-01-13 | Novo Nordisk A/S | Identification of ligands by selective amplification of cells transfected with receptors |
| JPH10152470A (ja) * | 1996-09-25 | 1998-06-09 | Yoshitomi Pharmaceut Ind Ltd | ピペラジン化合物 |
| EP1535912A1 (en) | 2000-04-28 | 2005-06-01 | Arcadia Pharmaceuticals Inc. | Muscarinic agonists |
| RU2269523C2 (ru) * | 2000-04-28 | 2006-02-10 | Акадиа Фармасьютикалз, Инк. | Мускариновые агонисты |
| US7550459B2 (en) * | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| BRPI0409523A (pt) * | 2003-03-28 | 2006-04-18 | Acadia Pharm Inc | método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica |
| US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| US9670209B2 (en) | 2013-03-15 | 2017-06-06 | Acadia Pharmaceuticals Inc. | Muscarinic agonists |
-
2014
- 2014-03-14 US US14/774,685 patent/US9670209B2/en not_active Expired - Fee Related
- 2014-03-14 EP EP14715518.8A patent/EP2976079A1/en not_active Withdrawn
- 2014-03-14 JP JP2016502306A patent/JP2016513677A/ja active Pending
- 2014-03-14 CA CA2903276A patent/CA2903276A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/026998 patent/WO2014152144A1/en not_active Ceased
- 2014-03-14 MX MX2015012043A patent/MX2015012043A/es unknown
- 2014-03-14 RU RU2015144155A patent/RU2015144155A/ru not_active Application Discontinuation
- 2014-03-14 TW TW103109294A patent/TW201446761A/zh unknown
- 2014-03-14 AU AU2014240139A patent/AU2014240139A1/en not_active Abandoned
- 2014-03-14 BR BR112015021271A patent/BR112015021271A2/pt not_active IP Right Cessation
- 2014-03-14 CN CN201480015640.8A patent/CN105120865A/zh active Pending
- 2014-03-14 KR KR1020157025205A patent/KR20150143439A/ko not_active Withdrawn
-
2015
- 2015-09-01 IL IL241001A patent/IL241001A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9670209B2 (en) | 2017-06-06 |
| CA2903276A1 (en) | 2014-09-25 |
| KR20150143439A (ko) | 2015-12-23 |
| WO2014152144A1 (en) | 2014-09-25 |
| TW201446761A (zh) | 2014-12-16 |
| EP2976079A1 (en) | 2016-01-27 |
| BR112015021271A2 (pt) | 2017-08-22 |
| JP2016513677A (ja) | 2016-05-16 |
| US20160039819A1 (en) | 2016-02-11 |
| AU2014240139A1 (en) | 2015-09-17 |
| CN105120865A (zh) | 2015-12-02 |
| MX2015012043A (es) | 2016-03-17 |
| RU2015144155A (ru) | 2017-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3065569T3 (pl) | Kompozycja | |
| HUE044039T2 (hu) | Biokatalitikus készítmény | |
| EP3006525A4 (en) | ASPHALT-URETHANE COMPOSITION | |
| GB201318489D0 (en) | Composition | |
| GB201319540D0 (en) | Composition | |
| GB201320919D0 (en) | Composition | |
| GB201317388D0 (en) | Composition | |
| GB201320303D0 (en) | Composition | |
| GB201319538D0 (en) | Composition | |
| GB201306984D0 (en) | Composition | |
| GB201322772D0 (en) | Composition | |
| GB201317196D0 (en) | Composition | |
| GB201307622D0 (en) | Composition | |
| IL241001A0 (en) | muscarinic agonists | |
| GB201420672D0 (en) | Composition | |
| GB201308502D0 (en) | Composition | |
| GB201301774D0 (en) | Composition | |
| IL243730A0 (en) | Vasopressin-2 receptor agonists | |
| GB201318394D0 (en) | Composition | |
| GB201312010D0 (en) | Receptor Agonists | |
| GB201306901D0 (en) | Combination | |
| GB201305622D0 (en) | Composition | |
| GB201320675D0 (en) | Composition | |
| AU5187P (en) | WES06 Westringia fruticosa | |
| GB201304105D0 (en) | Agonist |